Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. - Wikidata - awgldk - TriplyDB

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

http://www.wikidata.org/entity/Q51389775

about

Amyloid diseases of the heart: current and future therapies An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.The evolving use of serum free light chain assays in haematology.Amyloidosis: pathogenesis and new therapeutic options.Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Current perspectives on cardiac amyloidosis.Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Perspectives in treatment of AL amyloidosis.Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.The Imaging Diagnosis of Less Advanced Cases of Cardiac Amyloidosis: The Relative Apical Sparing Pattern Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.New and developing therapies for AL amyloidosis.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.Preclinical development of siRNA therapeutics for AL amyloidosis.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

P2860

Q27023836-774EC945-F709-41D3-847A-696091DBA6C8 Q33304297-A07407B2-9106-45B5-8A31-CC573452C419 Q34240595-D31919B2-A747-4B46-A9B6-B2A3065BFDCF Q34450428-BA947F04-C416-4610-9FDA-186CAB1EFCB9 Q34758218-F02D0FBD-8EE3-425E-96E6-580DAE50D45B Q35111771-08EC5EE3-85E1-4B6A-825B-D04E1317FFC1 Q35848844-0BCAAABC-DF08-48F2-A325-6C0710ECAD35 Q35849610-87522B27-930E-4C04-AC6C-AFAECD328856 Q35964900-3B474F07-0049-425E-BBAA-744D29FFC593 Q36384780-6ED72602-BE2B-4621-A4DF-EA83FD790676 Q36712121-51D46101-4E44-40A1-BB31-394F78E9C940 Q36779759-63E59029-C767-463F-A203-FDED0238640D Q36892637-59FCE83D-CD21-4D5D-ACF3-6FAF1B692165 Q36910372-9FED4654-52D5-445E-BE40-FA81997EF041 Q37045885-6F22A322-D727-41A3-85A2-93C07CF60967 Q37172003-CD584D38-404C-48A6-8A3F-76EA53720AD6 Q37370051-06D580A7-1410-4E5C-90CA-D163FB8F04C2 Q37697277-713B3568-633F-41BD-B1FD-D72C761C3797 Q37821496-30A67A11-E064-47FE-BD1A-5CBB45FA527E Q37904673-65016561-97FB-42F7-9933-C57FF0368EF6 Q37995198-F60D4565-F725-47E5-8B92-58DDC45650ED Q38168869-B0EA3AE1-6A56-4DE8-825B-82D60EB0E2B1 Q38779623-03B02F50-FFA7-4AE8-8351-4290E8160E01 Q38851025-068AF2C9-2B30-4684-B91D-A2A7FCCF068D Q40973226-998B3DC1-1F43-4962-998F-11CA4860BFB4 Q42543905-3D723570-9E84-4C70-B7FE-D7AB8DADE01D Q42867066-C51F04DA-3085-4BA9-B8E0-2BC6E6332CDE Q44060632-5712F418-7CFE-47C2-9700-DD6ACFADDCE3 Q44468671-D71904A7-096A-41C0-88CD-BF2A002B1AF2 Q46251291-52002133-EEC0-4431-9A39-E2E6306B35AC Q46680983-CC92A41F-21DE-4CC1-A9DF-2ABE50E9F7D3 Q46980729-2B08F5F4-8CDB-47A6-AA81-33994AA4A3B2 Q58853169-FB21F734-56AC-4E38-B28E-0AFE674EF85A Q58853185-A410E03B-8E55-43AE-AC86-12435FEA126E

P2860

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

http://www.wikidata.org/entity/Q51389775

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Serum free light-chain respons ...... for AL (primary) amyloidosis.

@en

Serum free light-chain respons ...... em cell transplantation for AL

@nl

type

label

Serum free light-chain respons ...... for AL (primary) amyloidosis.

@en

Serum free light-chain respons ...... em cell transplantation for AL

@nl

prefLabel

Serum free light-chain respons ...... for AL (primary) amyloidosis.

@en

Serum free light-chain respons ...... em cell transplantation for AL

@nl

P1433

Q51389775-08218A81-55D9-4A6C-BB9A-4C362FD81544

P1476

Q51389775-8F9D814F-258B-41AC-ADD5-173AAAFFD210

P2093

Q51389775-0C9B2D8D-B3C8-4545-9042-C6F1930A5D5B

Q51389775-2866AE4E-3445-4284-8B3D-28CE1A874B41

Q51389775-468B3B56-8758-42B6-A3AD-D3670851F5DF

Q51389775-6614C5AC-E9DC-435F-A26D-57DED73DDE23

P2860

Q51389775-01064AF5-864C-46EB-BB92-B276FFE05275

Q51389775-2E2B24D3-C9FC-43DE-9244-7AE3214FAE08

Q51389775-5DCEEFE8-A672-4A68-A489-CA506F77BCB4

Q51389775-8FD3FD4C-562C-4736-936C-F2250CC18D5B

Q51389775-EBADA3E0-5A9B-44D9-91E7-D4513D3F44F4

P2888

Q51389775-CF7D42D0-8A21-4827-B33C-E09C1A303B2D

P304

Q51389775-951DDE52-CC23-4EEF-A1D7-15F44A43E561

P31

Q51389775-9356A607-7BDD-43EE-82DF-B891C9657345

P356

Q51389775-7CEDE5FE-33D4-4D5B-ACEF-813BF12335EC

P407

Q51389775-7C96E9C7-2688-4AF5-B50F-CFC0FCC3D153

P433

Q51389775-8EEF06A2-F77F-4D5E-8D69-5AFB92D5C3EA

P478

Q51389775-6EAFF793-C8D6-4864-AA6B-534A92097EC3

P50

Q51389775-D9938003-6CEE-4E04-87DA-48F4C9C51C93

P577

Q51389775-DE7890D4-D548-43CF-AC7B-B6986919BA91

P5875

Q51389775-02F54238-22FC-449B-A7C7-C0E2014CFF26

P6179

Q51389775-E6B66054-866C-4254-9703-B025E9CBA6B0

P698

Q51389775-776DAE47-2FFD-442B-A52E-09C486DB46CA

P356

P1433

Bone Marrow Transplantation

P1476

Serum free light-chain respons ...... for AL (primary) amyloidosis.

@en

P2093

Magnani B

http://www.w3.org/2001/XMLSchema#string

Seldin DC

http://www.w3.org/2001/XMLSchema#string

Skinner M

http://www.w3.org/2001/XMLSchema#string

Wright DG

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

P2888

P304

597-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705106

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Vaishali Sanchorawala

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7701798

http://www.w3.org/2001/XMLSchema#string

P6179

1027034985

http://www.w3.org/2001/XMLSchema#string

P698

16044137

http://www.w3.org/2001/XMLSchema#string